The estimated Net Worth of Ram Sasisekharan is at least $27.8 Milion dollars as of 26 July 2010. Ram Sasisekharan owns over 33,930 units of Momenta Pharmaceuticals stock worth over $16,076,933 and over the last 20 years Ram sold MNTA stock worth over $11,745,644.
Ram has made over 37 trades of the Momenta Pharmaceuticals stock since 2005, according to the Form 4 filled with the SEC. Most recently Ram sold 33,930 units of MNTA stock worth $780,051 on 26 July 2010.
The largest trade Ram's ever made was selling 88,600 units of Momenta Pharmaceuticals stock on 21 April 2006 worth over $1,506,200. On average, Ram trades about 15,977 units every 43 days since 2005. As of 26 July 2010 Ram still owns at least 306,344 units of Momenta Pharmaceuticals stock.
You can see the complete history of Ram Sasisekharan stock trades at the bottom of the page.
Ram's mailing address filed with the SEC is C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE, MA, 02142.
Over the last 20 years, insiders at Momenta Pharmaceuticals have traded over $110,027,424 worth of Momenta Pharmaceuticals stock and bought 827,300 units worth $5,505,611 . The most active insiders traders include Christoph H Westphal, Craig A Wheeler oraz Peter Barrett. On average, Momenta Pharmaceuticals executives and independent directors trade stock every 6 days with the average trade being worth of $448,442. The most recent stock trade was executed by Ian Fier on 20 August 2020, trading 1,808 units of MNTA stock currently worth $94,323.
Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA.
Momenta Pharmaceuticals executives and other stock owners filed with the SEC include: